Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

The scheduled presentations cover clinical-trial and real-world analyses, but the announcement does not disclose study findings.

Rhea-AI Summary

Veracyte (VCYT) announced eight Decipher-focused studies slated for presentation at ASTRO 2026 in Boston.

Six oral presentations, including a quick-pitch session, and two posters are scheduled during the September 26–30 meeting. The studies use the Decipher Prostate Genomic Classifier test and whole-transcriptome data. They include analyses from Phase II and III clinical trials, GRID research and national real-world studies. Topics include assessing prostate cancer progression risk and identifying patients who may benefit from adding androgen-deprivation therapy to radiation.

Key Terms

whole-transcriptome, androgen-deprivation therapy, prognostic

3 terms

whole-transcriptome technical

"Decipher Prostate Genomic Classifier test and whole-transcriptome data"

The whole-transcriptome is the complete set of RNA messages produced by cells at a given time, capturing which genes are turned on or off and how strongly. For investors, it matters because this deep snapshot helps researchers identify drug targets, track disease markers, and measure how therapies change cellular behavior—similar to reading every email in an office to understand operations and spot problems or opportunities.

androgen-deprivation therapy medical

"including adding androgen-deprivation therapy (ADT) to radiation"

Androgen-deprivation therapy is a medical treatment that lowers or blocks male sex hormones (androgens), primarily testosterone, to slow or stop the growth of hormone-sensitive cancers, most commonly prostate cancer. Think of it as cutting off or shielding the fuel a tumor uses to grow. It matters to investors because it shapes demand for drugs, devices and long-term care, influences clinical trial results and regulatory decisions, and affects revenue and valuation in oncology-focused companies.

prognostic medical

"Decipher’s prognostic value in assessing disease risk"

Prognostic describes something that gives information about the likely future course or outcome of a condition, such as how severe a disease will become or how long it might last. For investors, prognostic markers, tests, or statements matter because they can change expectations about a drug’s market need, trial design, regulatory path, or long-term revenue—like a weather forecast that helps decide whether to carry an umbrella or change plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensification

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26–30 in Boston.

The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.

“The breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease.”

The following Decipher-focused studies will be presented at ASTRO 2026:

Oral Presentations

• Title: Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis
  Presenter: Shuang Zhao, M.D., M.S.E.
  Abstract: 6
  Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET
  Location: Grand Ballroom
  
  
• Title: The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002
  Presenter: Mark Hurwitz, M.D., FASTRO
  Abstract: 250
  Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET
  Location: Room 210
  
  
• Title: Genomic Stratification of Benefit From Short-Term Androgen Deprivation With Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of RTOG/NRG 0815
  Presenter: Angela Jia, M.D., Ph.D.
  Abstract: 312
  Date/Time: Tuesday, September 29, 3:55– 4:05 p.m. ET
  Location: Room 210
  
  
• Title: Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial
  Presenter: Abhishek Solanki, M.D., M.S.
  Abstract: 314
  Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET
  Location: Room 210
  
  
• Title: Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy
  Presenter: Krishnan Patel, M.D.
  Abstract: 315
  Date/Time: Tuesday, September 29, 4:25–4:35 p.m. ET
  Location: Room 210

Quick-Pitch Presentation

• Title: Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 1166
  Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET
  Location: Room 205

Poster Presentations

• Title: Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 3297
  Date/Time: Sunday, September 27, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A
  
  
• Title: Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis
  Presenter: Andrew Barsky, M.D.
  Abstract: 3226
  Date/Time: Tuesday, September 29, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A

Additional information is available through the ASTRO 2026 Annual Meeting program.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements regarding the potential role of genomic information in helping identify which patients may benefit from treatment intensification and helping clinicians navigate prostate cancer treatment decisions and personalize treatment decisions for patients across different stages of disease. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “may,” “potential,” “will,” and similar expressions. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described under the caption “Risk Factors” in Veracyte’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the United States and selected countries.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780